- Home
- CCBG vs SYRE Comparison
CCBG vs SYRE Comparison
Compare CCBG & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCBG
- SYRE
- Stock Information
- Founded
- CCBG 1895
- SYRE 2013
- Country
- CCBG United States
- SYRE United States
- Employees
- CCBG N/A
- SYRE N/A
- Industry
- CCBG Major Banks
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- CCBG Finance
- SYRE Health Care
- Exchange
- CCBG Nasdaq
- SYRE Nasdaq
- Market Cap
- CCBG 701.6M
- SYRE 841.4M
- IPO Year
- CCBG N/A
- SYRE 2016
- Fundamental
- Price
- CCBG $40.42
- SYRE $17.79
- Analyst Decision
- CCBG Buy
- SYRE Buy
- Analyst Count
- CCBG 2
- SYRE 5
- Target Price
- CCBG $39.50
- SYRE $55.00
- AVG Volume (30 Days)
- CCBG 44.2K
- SYRE 632.6K
- Earning Date
- CCBG 07-22-2025
- SYRE 08-06-2025
- Dividend Yield
- CCBG 2.38%
- SYRE N/A
- EPS Growth
- CCBG 14.00
- SYRE N/A
- EPS
- CCBG 3.42
- SYRE N/A
- Revenue
- CCBG $240,944,000.00
- SYRE N/A
- Revenue This Year
- CCBG $10.45
- SYRE N/A
- Revenue Next Year
- CCBG $3.50
- SYRE N/A
- P/E Ratio
- CCBG $11.82
- SYRE N/A
- Revenue Growth
- CCBG 8.96
- SYRE N/A
- 52 Week Low
- CCBG $30.99
- SYRE $10.91
- 52 Week High
- CCBG $42.33
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- CCBG 51.16
- SYRE 61.20
- Support Level
- CCBG $40.40
- SYRE $16.16
- Resistance Level
- CCBG $42.33
- SYRE $18.31
- Average True Range (ATR)
- CCBG 0.89
- SYRE 0.96
- MACD
- CCBG -0.16
- SYRE 0.20
- Stochastic Oscillator
- CCBG 13.57
- SYRE 84.18
About CCBG Capital City Bank Group
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services among others through its banking offices in Florida, Georgia, and Alabama.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.